Asia Fresh News

Asia Fresh Stories

Archive for September 3rd, 2012

Western viewers fall behind in the web-connected TV revolution

leave a comment »

NUREMBERG, Germany, Aug. 31, 2012 /PRNewswire-Asia/ — People in markets such as China, Brazil and India better exploit the opportunities offered by web-connected television, compared to countries such as the UK, US and Germany. This is according to research carried out across thirteen countries by GfK*s consumer research experts. The study found that western consumers are stuck in an “analogue” mindset, whereas viewers in emerging markets are more likely to embrace the digital capabilities of Connected TV.

GfK research shows that a far higher proportion of Chinese, Korean and Indian consumers have used the functionalities of Smart TV in the past months, compared to those in Western markets.

Connected TV usage:
China 44%
S. Korea 18%
India 17%
Brazil 14%
Turkey 13%
UK 11%
USA 11%
Mexico 11%
Spain 8%
Germany 8%
Belgium 6%
Russia 5%
Netherlands 5%
GfK*s findings show that “Social TV” has yet to fully take-off. Globally, just 28% of viewers said that they found programmes that they can interact with to be more interesting to watch. And just 25% thought that tweeting and commenting on programmes “enhances the viewing experience.”

Viewers in countries such as China, Brazil and India are more motivated by programmes they can interact with than those in markets such as the UK, US and Germany[1].

Richard Preedy, at GfK, said: ※Our findings suggest that broadcasters need to integrate their social elements far more engagingly into the fabric of the programme, in order to entice the viewer*s interaction.§

Across all markets, the ability to connect to the internet is less important than price, screen size and display technology, when buying a new TV. But the West is more indifferent than the emerging markets, with only 26% of UK and 29% of US consumers saying they look out for a net enabled set, compared to 61% in India and 64% in China.

You can read more the full press release here:


[1] % agreeing with statement &Programmes I can interact with are much more interesting to watch* Brazil 42%, China 61%, India 59% vs. UK 16%, USA 18%, Germany 15%

Research contact:
Ryan Garner )

PR contact:
Amanda Wheeler
+44 7919 624688


Written by asiafreshnews

September 3, 2012 at 3:30 pm

Posted in Uncategorized

Perfect World to Launch Open Beta Testing for Martial Arts MMORPG “Return of the Condor Heroes” on September 20

leave a comment »

BEIJING /PRNewswire-Asia/ — Perfect World Co., Ltd. (NASDAQ: PWRD) (“Perfect World” or the “Company”), a leading online game developer and operator based in China, announced it will launch the open beta testing for its 2D turn-based martial arts MMORPG, “Return of the Condor Heroes,” on September 20, 2012.
“Return of the Condor Heroes” is Perfect World’s new MMORPG adapted from Louis Cha’s acclaimed martial arts novel of the same name. In a traditional 2D turn-based online gaming environment, the game adopts some advanced 3D technologies to render delicate visual effects and various fun options to players. Providing a refreshing gaming experience for fans of traditional 2D games, “Return of the Condor Heroes” introduces exciting features, including “Qinggong,” a gameplay that adopts a style of martial arts with gravity-defying moves, and a powerful pet system.
Mr. Michael Chi, Chairman and Co-CEO of Perfect World, commented, “I am very pleased to present ‘Return of the Condor Heroes’ to our players this fall. We have always committed ourselves to developing high-quality titles that incorporate the richness of Chinese culture. With this new self-developed, turn-based online game equipped with various creative features, we look forward to bringing more entertaining experiences for our global players and introducing them to the charm of Chinese culture.”
About Perfect World Co., Ltd. (
Perfect World Co., Ltd. (NASDAQ: PWRD) is a leading online game developer and operator based in China. Perfect World primarily develops online games based on proprietary game engines and game development platforms. Perfect World’s strong technology and creative game design capabilities, combined with extensive knowledge and experiences in the online game market, enable it to frequently and promptly introduce popular games designed to cater changing customer preferences and market trends. Perfect World’s current portfolio of self-developed online games includes massively multiplayer online role playing games (“MMORPGs”): “Perfect World,” “Legend of Martial Arts,” “Perfect World II,” “Zhu Xian,” “Chi Bi,” “Pocketpet Journey West,” “Battle of the Immortals,” “Fantasy Zhu Xian,” “Forsaken World,” “Dragon Excalibur” and “Empire of the Immortals;” an online casual game: “Hot Dance Party;” and a number of web games and social networking games. While a substantial portion of the revenues are generated in China, Perfect World operates its games in North America, Europe and Japan through its own subsidiaries. Perfect World’s games have also been licensed to leading game operators in a number of countries and regions in Asia, Latin America, Australia, New Zealand, and the Russian Federation and other Russian speaking territories. Perfect World intends to continue to explore new and innovative business models and is committed to maximizing shareholder value over time.
Safe Harbor Statements
This press release contains forward-looking statements. These statements constitute forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Potential risks and uncertainties include, but are not limited to, Perfect World’s limited operating history, its ability to develop and operate new games that are commercially successful, the growth of the online game market and the continuing market acceptance of its games and in-game items in China and elsewhere, its ability to protect intellectual property rights, its ability to respond to competitive pressure, its ability to maintain an effective system of internal control over financial reporting, changes of the regulatory environment in China, and economic slowdown in China and/or elsewhere. Further information regarding these and other risks is included in Perfect World’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Perfect World does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
For further information, please contact
Perfect World Co., Ltd.
Vivien Wang – Vice President, Investor Relations & Corporate Communications
Joanne Deng – Investor Relations Manager
Tel: +86-10-5780-5700
Fax: +86-10-5780-5713
Christensen Investor Relations
Patty Bruner
Tel: +1-480-614-3036
Fax: +1-480-614-3033
Teal Willingham
Tel: +86-10-5826-4988
Fax: +86-10-5826-4838
Source: Perfect World Co., Ltd.

Written by asiafreshnews

September 3, 2012 at 12:18 pm

Ma Ze Hua, President, COSCO Group, & Ng Yat Chung, CEO, NOL Group, to Deliver Keynote Speeches at 6th Annual TPM Asia Conference

leave a comment »

NEWARK, N.J. /PRNewswire-Asia/ — The Journal of Commerce confirmed today that two of the most senior executives in the container shipping industry globally will participate as keynote speakers at the 6th Annual TPM Asia conference. Ma Ze Hua, President of the COSCO Group and Ng Yat Chung, president and CEO of the NOL Group, parent of container line APL, will deliver keynote speeches at the UBM Global Trade organized conference, set for October 17-18 in Shenzhen, China, home to one of the world’s largest container ports.
Both executives will speak to the current state of container shipping and the major issues facing customers, carriers, ports and the broader economy as the industry takes stock of 2012 and begins to look toward 2013. They will address a key theme of the conference, which is how the industry can move toward a less volatile and more predictable future, bringing greater predictability and value to the global supply chains that depend on an effective container shipping system.
Ma Zehua was named Director of the Board, President and Deputy Secretary of Party Committee of China Ocean Shipping (Group) Company (“COSCO Group”) in August 2011. He was formerly President of COSCO (UK) Ltd., General Manager of the Development Division and Assistant President of China Ocean Shipping (Group) Company, President of COSCO America Inc.
Ng Yat Chung was appointed Group President and Chief Executive Officer of NOL beginning October 2011. Prior to joining NOL, Ng was a Senior Managing Director at Temasek Holdings (Private) Limited. Before joining Temasek Holdings, he was the Chief of Defense Force in the Singapore Armed Forces (SAF).
Other confirmed speakers and panelists include:
Lucas Vos, Chief Commercial Officer, Maersk Line
Hua Joo Tan, Executive Consultant, Alphaliner
Mario Moreno, Economist, The Journal of Commerce
Mark Szakonyi, Associate Editor, The Journal of Commerce
Some of the planned session and topics include:
The Economic Environment for Container Shipping
Finding Value in BCO/Shipper and Carrier Relationships
China as a Driver for Containerized Trade – How is it Changing?
The conference will be hosted by the Shenzhen Municipal Port Administration, and organized by The Journal of Commerce. Sponsors and confirmed participating companies include Shekou Container Terminals, Chiwan Container Terminal, DaChan Bay Terminal One, Yantian International Container Terminals, APL, APL Logistics, CMA CGM, Maersk Line, OOCL, Port of Houston Authority Guangzhou Port Group, Inttra, Damco, Modern Terminals and Emirates Shipping Line.
Well over 600 attendees flocked to the 5th Annual TPM Asia conference, held at the Intercontinental in Shenzhen, China on October 11-12th. TPM Asia also attracted 100+ shippers, like Sony, Staples, Target, The Home Depot and more. TPM Asia is now clearly established as the largest and most important annual container shipping conference in Asia. This year, leading figures in the industry will take on the major issues and challenges, offering valuable insights, predictions, and guidance for the attendees.
For more information, or to register for the event, please visit Its American counterpart, TPM, the world’s largest container shipping conference, will be held on March 3-6, 2013 in Long Beach, California. For more information on TPM, please visit:
About The Journal of Commerce: Since 1827, JOC has been the most trusted source of intelligence for international logistics executives to help them plan global supply chains and better manage day-to-day transportation of goods and commodities in the United States and internationally. To become a member of The Journal of Commerce, please visit:
About UBM Global Trade — UBM Global Trade is the leading provider of proprietary data, news, business intelligence and analytical content supporting commercial maritime, rail, trucking, warehousing and logistics industries worldwide. The company’s portfolio of more than 100 online, print and interactive workflow business solutions includes The Journal of Commerce, Breakbulk, RailResource, PIERS and an array of international trade and transportation databases and directories. UBM Global Trade, a subsidiary of UBM, is headquartered in Newark, NJ, with offices throughout the United States. For more information, explore or call 800-223-0243 (+1-973-848-7250 outside the U.S. or Canada).
Greg March, Asia Director
The Journal of Commerce

Written by asiafreshnews

September 3, 2012 at 11:15 am

Posted in Uncategorized

Tagged with

Sihuan Pharmaceutical Announces 2012 Interim Results

leave a comment »

– Revenue and Net Profit Surged 40.3% and 21.2%, Respectively –
– Further Diversified Product Portfolio to Capture Future Growth –
– Grew Sales of Ten Major Products by over 50% –

HONG KONG /PRNewswire-Asia/ — Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) (“Sihuan Pharmaceutical” or the “Company”), a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China’s prescription drug market, today announced its interim results for the six months ended 30 June 2012.
Financial Highlights
For the Six Months Ended 30 June
Key Income Statement Items RMB ‘000 Change %
2012 2011
Revenue 1,389,297 990,568 40.3%
Gross Profit 1,071,419 774,730 38.3%
Operating Profit 533,425 446,326 19.5%
Profit Attributable to Equity Owners
of the Company 461,445 380,685 21.2%
Dividend per Share (RMB Cents) 3.1 1.9 N/A
Special Dividend per Share (RMB Cents) Nil 7.8 N/A

During the period under review, the Company continued to strengthen its cardio-cerebral vascular (“CCV”) drug business while promoting sales of its products in other therapeutic areas. The Company continued to achieve sustainable growth, with revenue increasing by 40.3% to RMB1,389.3 million and gross profit rising 38.3% year-on-year to RMB1,071 million. Net profit attributable to the Company’s equity owners increased by 21.2% to RMB461.4 million. The Board of Directors has also recommended an interim dividend of RMB3.1 cents per share (2011: RMB1.9 cents) for the six months ended 30 June 2012.
Dr. Che Fengsheng, Chairman and CEO of the Company, said, “Despite a challenging operating environment in the first half of the year, we maintained our growth momentum and this was largely driven by our diversified and optimized product portfolio and strengthened sales and marketing strategies. We made significant progress in deepening penetration in current markets as well as expanding into new markets, enhancing our sales and marketing network, and strengthening our R&D and production capabilities. Further, we effectively promoted the sales of various established and promising products such that ten major products achieved sales growth of over 50%, and further strengthened our leading position as the largest CCV franchise in China. We have also grown to the be the ninth largest pharmaceutical company in the prescription drug market in China which positions us to maximize the immediate and long-term market opportunities.”
Robust Growth for Major Products
CCV Products
Benefitting from the broader revenue base from a further diversified product portfolio, sales of CCV products recorded satisfactory growth of 46.1% to RMB1,277.4 million, accounting for 91.9% of total revenue.
Sihuan Pharmaceutical has stepped up its efforts to further penetrate existing markets with its established products while expanding the presence of its promising products in new markets. As a result, sales revenue for Qingtong, GM1, Qu’Ao and Chuanqing grew by 72.2%, 63.0%, 38.4% and 11.0% to RMB29.1 million, RMB96.1 million, RMB40.8 million and RMB42.8 million, respectively. Sales of various promising products, such as Aoliankang, Yuanzhijiu, Yimaining and Yeduojia, also increased significantly by 272.6%, 238.8%, 157.7% and 76.6%, respectively. Sales volume of Kelinao and Anjieli were impacted by slower-than-expected progress in the lifting of medical reimbursement restrictions. As for Oudimei, delays in provincial drug tendering and the alignment of the Company’s distribution network affected its growth.
Nevertheless, the Company believes that the impact is temporary. In the second half of the year, outstanding provincial drug tenders are expected to complete gradually and the mentioned factors are expected to fade. Further, sales of these products are expected to gradually improve during the second half of the year. At the same time, the Company plans to enhance efforts in academic promotions and expand its sales and marketing team. Taken together, this will enhance the Company’s overall performance in the balance of the year and going forward.
Non-CCV Products
Despite that sales of anti-infective drugs decreased due to stricter restrictions on clinical use, the Company avhieved robust sales growth of its nervous system, respiratory and metabolism drugs. As a result, sales of these drugs grew by approximately 19.6% to RMB71.0 million compared to the same period of last year, accounting for approximately 5.1% of the Company’s total revenue. Sales of Ren’Ao, Zhuo’Ao and Bi’Ao surged 101.3%, 61.8% and 35.8%, respectively.
Sound Progress in Research and Development (“R&D”)
To strengthen its industry-leading position, the Company continued to further its efforts in R&D. Various projects have made solid progress during the first half of 2012. For example, Roxatidine Acetate Hydrochloride for Injection, Sihuan Pharmaceutical’s first-to-market generic drug, passed on-site inspection conducted by the State Food and Drug Administration (“SFDA”) in May 2012. With approval for production expected in the near future, the Company plans to launch the product in the second half of the year.
In addition, two other drugs, the exclusive Category IV new drug Cinepazide Mesilate and the Category I innovative drug L-Phencynonate Hydrochloride, have both progressed into more advanced phases of clinical trial. Another generic drug, Nalmefene Hydrochloride, is pending on-site inspection by the SFDA. As of the end of June 2012, the Company has obtained eight new patents.
Strengthened Production and Quality Management
The Company has commenced upgrades of its production bases in Beijing, Jilin and Liaoning in compliance with the new Good Manufacturing Practice (“GMP”) standards. Langfang Sihuan Gaobo Pharmaceutical Co., Ltd, the Company’s active pharmaceutical ingredient (“API”) plant, passed the new GMP standards in 2011 and commenced production thereafter. During the Period, API plant produced over 10 APIs with aggregate production exceeding 15 tonnes. In addition, the Company has lowered costs and improved production yield and capacity of its newly acquired facilities.
Outlook for the Second Half of 2012
Despite the macro policy headwinds brought on by various medical reform measures, the Company believes that the pharmaceutical industry will continue to be one of the fastest-growing sectors in 2012. Rising per capita subsidy standards for medical insurance and the maximum reimbursements for medical treatments are expected to be catalysts in driving industry growth in 2012 and beyond. Other favourable factors such as the accelerated pace of urbanization and the aging population, along with the 12th Five-year Plan stipulated by the Chinese government, will further fuel robust market growth over the long-term.
Looking into the second half of the year, the Company will continue its two-pronged sales and marketing strategy to boost sales of its established and fast-growing promising products by furthering its penetration into current provincial markets and entering new markets. To that end, the Company will increase marketing efforts by expanding its sales force and stepping up academic promotion to further brand recognition. It will also strive to secure tenders for established products at stable price levels to expand market coverage of promising products.
To diversify its product offering, the Company plans to make further investments in the R&D of key projects in the pipeline, particularly for first-to-market generic drugs. The aim is to shorten the time needed to commercialize the Company’s products. Meanwhile, the Company will seek to explore collaborative opportunities to maximize sources of new R&D projects, shorten the product development cycle, further enhance technology platforms, and strengthen its overall R&D capabilities.
Dr. Che concluded, “2012 is expected to be the most challenging year thus far for the Company and while it is proving to be a time of transition and adaptation, we are doing a very good job navigating through this. Facing intensified market competition as well as macro headwinds, the Company’s strategic internal alignment and adjustments in 2012 constitute vital groundwork for our further development in the second half of this year and beyond. We are confident that by leveraging our highly-diversified product portfolio and strong R&D capabilities, we will be able to deliver strong and consistent returns to our shareholders over the long-term.”
About Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China’s prescription drug market by market share. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network, and strong research and development capabilities. The company’s current products encompass the top five medical therapeutic areas in China: cardio cerebral vascular system, central nervous system, metabolism, oncology and anti-infectives. Their major products such as Kelinao, Anjieli, Chuanqing, Qu’Ao GM1 and Oudimei are widely used in the treatment of various cardio-cerebral vascular diseases.
Source: Sihuan Pharmaceutical Holdings Group Ltd.

Written by asiafreshnews

September 3, 2012 at 10:01 am